BioVie Data at International Congress of Parkinson’s Disease and Movement Disorders

 

• New preclinical data characterizing NE3107 mechanism of action featured in oral presentation
• Phamacokinetic data from Phase 2a study supports potential co-administration of NE3107 with carbidopa/levodopa
• Separate analysis of Phase 2a study data shows evidence of motor effects of NE3107 independent of levo-dopa/ carbidopa, supporting further investigation of NE3107 as first line therapy in Parkinson’s Disease

https://www.biospace.com/article/releases/biovie-presents-data-for-ne3107-at-2023-international-congress-of-parkinson-s-disease-and-movement-disorders/